Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. The deployment marks TechForce’s first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies’ April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications. Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service (RaaS) platform, which combines advanced hardware, intelligent AI-enhanced software, and scalable operational infrastructure.
This milestone demonstrates that TechForce's autonomous robotic systems can improve operational efficiency, workflow consistency, and scalability across new sectors. For Oncotelic, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, the collaboration could streamline laboratory operations and accelerate research workflows. The implications extend beyond the two companies: the successful deployment suggests that AI-enhanced robotics can address labor shortages, reduce human error, and enhance reproducibility in pharmaceutical labs, potentially lowering development costs and speeding time-to-market for new therapies.
For the broader industry, this move signals a growing convergence between robotics and life sciences. As TechForce expands its RaaS model—which allows clients to access robotic solutions without large upfront capital investments—more pharmaceutical and biotech firms may adopt automation to stay competitive. Nightfood’s focus on healthcare and life sciences as growth markets aligns with industry trends toward automation, driven by the need for precision, safety, and cost efficiency in drug development and manufacturing.
The joint development agreement between TechForce and Oncotelic, formed in April 2026, sets the stage for further collaboration. With LIM-E now operational, the partners will gather data to refine workflows and identify additional automation opportunities. This could lead to broader adoption of robotics in laboratory logistics, such as sample handling, inventory management, and equipment maintenance, as well as in manufacturing support roles.
Investors and industry observers will watch for updates on Phase 2 objectives, which may involve scaling the deployment or integrating more advanced AI capabilities. For now, the deployment of LIM-E represents a tangible step toward automating routine laboratory tasks, freeing skilled scientists to focus on higher-value research. As Nightfood continues to develop its TechForce Robotics platform, the company positions itself at the intersection of robotics and life sciences, a market with substantial long-term potential.
